

Basingstoke, Southampton and Winchester

District Prescribing Committee (DPC)

Recommendations of the meeting of 14th June 2016

Supported or limited support e.g. Specialist recommendation

- **Sacubitril Valsartan (Entresto®)** - is an angiotensin receptor neprilysin inhibitor and is recommended as a treatment option for patients with symptomatic heart failure in line with NICE TA388: That is for patients suffering NYHA class II to IV symptoms, with left ventricular ejection fraction of 35% or less and who are already taking a stable dose of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor-blocker (ARB).
Sacubitril valsartan replaces the ACEI or ARB on which the patient has previously been stabilised. Additional ACEI or ARB should not be co-administered and any ACEI treatment should be discontinued at least 36 hours before commencing sacubitril valsartan.
Treatment should only be started by a heart failure specialist with access to a multidisciplinary heart failure team. However it has been classed locally as an amber drug and prescribing may be transferred to primary care once titration to a stable maintenance dose has been achieved.
The DPC supports the availability of sacubitril valsartan in line with the NICE guidance.
- **Hampshire Nalmefene shared care guideline** - These were approved for use and will be available on the shared care guidelines section of the West Hampshire CCG website shortly (see links below).
- **Brivaracetam (Briviact®)** - This was supported for use locally as an adjunctive therapy in the treatment of partial onset seizures. Its use should be restricted to selected patients (e.g. unable to tolerate levetiracetam and other antiepileptic's (as detailed in NICE CG137) are not suitable or ineffective). Treatment should be initiated by specialist and classed as an Amber drug.

Not supported

- **Racecadotril (Hidresec®) for the treatment of acute diarrhoea in infants and children**- the DPC did not support the use of this locally as there is a lack of meaningful clinical or economic data applicable to the UK to support the use of this therapy.

Other Information / Reminders

- **Chronic non-malignant pain guidelines summary sheet** – A two sided summary sheet of these guidelines were approved for use and are available on the guidelines section of the West Hampshire CCG website (see links below).
- **Biosimilar medicines position statement and guidance** –The DPC has endorsed this guidance which will be available on the guidelines section of the West Hampshire CCG website shortly (see links below).
- **Hospital medicine helplines**- this is a reminder that both University Hospital Southampton (UHSFT) and Hampshire Hospitals (HHFT) have a medication help line for post discharge queries, The number is detailed on the bottom of the discharge summaries and also listed below

HHFT	01962 824294
UHSFT	023 8120 6907 (patients/carers)
	023 8120 6908/9 (healthcare professionals)

- **Insulin Degludec (Tresiba®) 100units/ml** – a reminder that this ultra-long acting insulin analogue is AMBER locally, initiated and stabilised by specialist for difficult to manage patients with type 1 diabetes.

➤ DPC summaries are available at:

<http://www.westhampshireccg.nhs.uk/downloads/categories/medicines/district-prescribing-committee>

➤ Guidance documents are available at:

<http://www.westhampshireccg.nhs.uk/downloads/categories/medicines/guidance>